CoChat

Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open‐label pilot study

Open access
Tremaine, W. J., Brzezinski, A., Katz, J. A., Wolf, D. C., Fleming, T. J., Mordenti, J., Strenkoski‐Nix, L. C., Kurth, M. C., THE AXYS ULCERATIVE COLITIS STUDY GROUP · 2002 · Alimentary Pharmacology & Therapeutics
Cited by 90

The DOI matches its Crossref record.

Abstract

Background: Mast cells isolated from the colonic mucosa in active ulcerative colitis appear to be partially degranulated, suggesting the release of tryptase. Aim: To investigate the safety and activity of APC 2059, a highly specific tryptase inhibitor, in the treatment of ulcerative colitis. Methods: This was an open‐label, Phase 2, multicentre pilot study in patients with mildly to moderately active ulcerative colitis, with a disease activity index of 6–9 on a 12‐point scale. Fifty‐six adults received 20 mg APC 2059 subcutaneously twice daily and 53 completed 28 days of treatment. The primary end‐point was response, defined as a final disease activity index of ≤ 3. Supplementary analyses were also performed. Results: Sixteen (29%) of 56 patients responded. Five (9%) showed complete remission (disease activity index=0). Twenty‐seven (49%) improved, with a final disease activity index of ≤ 3 or a four‐point reduction. Improvement or normalization in each category of the disease activity index was as follows: stool frequency, 64%; bleeding, 64%; endoscopy, 50%; physicians' rating, 63%. There were no significant relationships between outcome and pharmacokinetics. The most common adverse events were related to the injection site (32.1%). Conclusions: In this pilot study, the tryptase inhibitor APC 2059 was safe and there was evidence of activity in the treatment of ulcerative colitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2002.01194.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 90

Metadata

Authors
Tremaine, W. J., Brzezinski, A., Katz, J. A., Wolf, D. C., Fleming, T. J., Mordenti, J., Strenkoski‐Nix, L. C., Kurth, M. C., & THE AXYS ULCERATIVE COLITIS STUDY GROUP
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2002-03
Volume
16
Issue
3
Pages
407-413
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W1991409953
Cited by
90
References
0
FWCI
2.50
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open‐label pilot study. https://app.cochat.ai/papers/10.1046/j.1365-2036.2002.01194.x
The paper
Tremaine, W. J., Brzezinski, A., Katz, J. A., Wolf, D. C., Fleming, T. J., Mordenti, J., Strenkoski‐Nix, L. C., Kurth, M. C., & THE AXYS ULCERATIVE COLITIS STUDY GROUP. (2002). Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open‐label pilot study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2002.01194.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.